Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with (...)
Site référencé: The Economic Times
The Economic Times
Defence ETFs gain 17% in one week. Should you add to your portfolio ?
17/05/2025
7 mutual funds reduce stake in 19 midcap stocks in April
17/05/2025
Cochin Shipyard among 10 smallcap stocks surge up to 57% this week
17/05/2025
Street Favourite ! SBI, Tata Motors among 10 large-cap stocks analysts expect to rally up to 32%
17/05/2025
For Trump, adulation and no risk of protests made the Gulf a dream trip
17/05/2025
Battered Wall Street short brigade is refusing to admit defeat
17/05/2025
